Skip to content

A Single-Centered Clinical Study to Evaluate the Safety and Efficacy of Polyethylene Glycol 3350 and Electrolytes for Oral Solution in Patients undergoing Colonoscopy or Intestinal Surgery

A Randomized, Open-Label, Single-Centered Clinical Study to Evaluate the Safety and Efficacy of Polyethylene Glycol 3350 and Electrolytes for Oral Solution in Patients undergoing Colonoscopy or Intestinal Surgery - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/069347
Enrollment
32
Registered
2024-06-21
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: Polyethylene Glycol 3350 + Electrolytes for Oral Solution: Polyethylene Glycol 3350 + Electrolytes for Oral Solution will be given to subjects undergoing colonoscopy or intestinal surge

Sponsors

TIL Healthcare Pvt. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects in the age group of 18 to 65 years. 2. Subjects with no bowel surgical procedure. 3. Subjects who have to undergo colonoscopy or intestinal surgery. 4. Willingness to provide written informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1.Pregnant women and lactating mother. 2.Subjects with colonic resections and/or ileostomies. 3.Inflammatory bowel disease. 4.Colonic optimization by prior colonoscopy with poor preparation. 5.Oral iron intake in the past 10 days. 6.Subjects who need Emergency colonoscopy, have Diabetes or Chronic kidney disease requiring dialysis. 7.Subjects with coexisting features of acute systemic disease like septicemia, meningitis, pneumonia, etc. 8.Subjects with symptoms or suspicion of an organic lesion of the digestive tract, or with undiagnosed abdominal pain or rectal bleeding or other GI disorder especially ulcerative colitis, Crohn’s disease, history of carcinomas of the bowel, malabsorption syndrome, intolerance to certain food types (lactose). 9.Participation in any clinical trial in the last 3 months prior to screening. 10.Hypersensitivity to any of the components composed in preparations. 11.Severe psychiatric illness (schizophrenia). 12.Low IQ to understand bowel preparation. 13.Severe constipation of less than 1 weekly stool. 14.Chronic diarrhea with high rate of 4 or greater than 4 daily evenly loose consistency stools for more than 4 weeks. 15.Unbalanced heart diseases (ischemic cardiopathology, congestive heart failure, unstable angina, arrhythmias and untreatable high blood pressure). 16.Presence of any other medical or surgical condition which as per the judgment of the principal investigator is not conducive for trial participation.

Design outcomes

Primary

MeasureTime frame
To assess the efficacy of Polyethylene Glycol 3350 + Electrolytes for Oral Solution in bowel cleaning. This will be assessed using the Boston Bowel Preparation Scale and Ottawa Bowel Preparation Scale.Timepoint: Day 1, 10

Secondary

MeasureTime frame
The satisfaction and tolerability of the product by the subjects including documentation of Adverse Events and Serious Adverse Events.Timepoint: Day 1,10

Countries

India

Contacts

Public ContactSathyavathi LM

Good Life Hospital

drmanju1910@gmail.com9900282899

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026